問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Linkou Chang Gung Medical Foundation

List

2449Cases

2023-05-01 - 2034-07-31

Phase III

An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)

  • Condition/Disease

    Relapsed Refractory Multiple Myeloma (RRMM)

  • Test Drug

    Linvoseltamab

Participate Sites
11Sites

Recruiting11Sites

2023-07-01 - 2029-08-10

Phase III

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

  • Condition/Disease

    Hair Diseases

  • Test Drug

    Baricitinib

Participate Sites
6Sites

Recruiting6Sites

2021-03-01 - 2024-12-10

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-12-31 - 2023-12-31

Phase II

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects with Sjögren’s Syndrome (SS)

  • Condition/Disease

    Sjögren’s Syndrome (SS)

  • Test Drug

    VIB4920

Participate Sites
5Sites

Recruiting5Sites

2021-08-01 - 2023-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2018-03-08 - 2021-07-04

Phase III

A PHASE 3 MULTI-CENTER, LONG-TERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB, WITH OR WITHOUT TOPICAL MEDICATIONS, ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS

  • Condition/Disease

    Atopic dermatitis (AD)

  • Test Drug

    PF-04965842

Participate Sites
9Sites

Recruiting9Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2019-04-01 - 2025-06-30

Phase II

A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

  • Condition/Disease

    Pancreatic Adenocarcinoma

  • Test Drug

    Zolbetuximab (IMAB362)

Participate Sites
8Sites

Recruiting8Sites

2019-12-01 - 2022-12-20

Phase III

A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, Followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women in Asia Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause

  • Condition/Disease

    Severe Vasomotor Symptoms (Hot Flashes)

  • Test Drug

    Fezolinetant

Participate Sites
11Sites

Not yet recruiting8Sites

Recruiting1Sites

Terminated2Sites

2014-05-31 - 2017-12-31

Phase II

BOTOX® Treatment of Masseter Muscle Hypertrophy

  • Condition/Disease

    BOTOX® Treatment of Masseter Muscle Hypertrophy

  • Test Drug

    BOTOX

Participate Sites
4Sites

Terminated4Sites

2010-09-30 - 2010-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 222 223 224 225 226 245
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB